188 Rhenium nanoliposome biodegradable alginate microsphere - Plus Therapeutics
Alternative Names: 188RNL-BAM; Rhenium-188 nanoliposome biodegradable alginate microsphereLatest Information Update: 22 Feb 2024
At a glance
- Originator Plus Therapeutics
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Liver cancer; Liver metastases
Most Recent Events
- 21 Feb 2024 Plus Therapeutics announces intention to submit IND application for Liver cancer, in 2024 (Plus Therapeutics pipeline, February 2024)
- 21 Feb 2024 Plus Therapeutics announces intention to submit IND application for Liver metastases in 2024 (Plus Therapeutics pipeline, February 2024)
- 25 Jan 2023 Plus Therapeutics files for PCT Application for, "Radiolabeled Liposomes and Methods for Treating Leptomeningeal Metastases" in the US